3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
12
Carcinoma, Non-Small-Cell Lung
6
Lung Neoplasms
5
Breast Diseases
4
Thoracic Neoplasms
3
Respiratory Tract Neoplasms
3
Neoplasms
3
Lung Diseases
3
Bronchial Neoplasms
3
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Melanoma
2
Kidney Neoplasms
2
Endocrine Gland Neoplasms
2
Digestive System Neoplasms
2
Respiratory Tract Diseases
1
Ovarian Neoplasms
1
Ovarian Diseases
1
Neoplasms by Site
1
Mammary Neoplasms, Animal
1
Hodgkin Disease
1
Fallopian Tube Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Bronchogenic
1
Advanced Breast Cancer
1
Interventions
Brentuximab Vedotin
27
pembrolizumab
13
Nivolumab
11
Dacarbazine
8
Vinblastine
7
Doxorubicin
7
Gemcitabine
6
Bendamustine Hydrochloride
6
plerixafor
5
fludarabine
4
Rituximab
4
Granulocyte Colony-Stimulating Factor
4
Cyclophosphamide
4
Azacitidine
4
abexinostat
3
Melphalan
3
Filgrastim
3
Etoposide
3
Busulfan
3
Bleomycin
3
umbralisib
2
relatlimab
2
pegfilgrastim
2
mocetinostat
2
itacitinib
2
givinostat hydrochloride
2
givinostat
2
fludarabine phosphate
2
durvalumab
2
cc-486
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hodgkin Disease
×
entinostat
×
Clear all
NCT00866333
2019-10-22
ENGAGE-501
Syndax Pharmaceuticals
Phase 2
Terminated
49 enrolled
12 charts